Bimatoprost (Lumigan®) is an agonist at the cloned human ocular FP prostaglandin receptor: Real-time FLIPR-based intracellular Ca2+ mobilization studies

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 68, Issue 1, 2003, Pages 27-33

  Sharif, N A ^a   Kelly, C R ^a   Williams, G W ^a  

^a Alcon Research Limited   (United States)

Author keywords

Bimatoprost; Calcium mobilization; FLIPR; FP receptor; Glaucoma; Lumigan ; Ocular hypertension; Pro drug

Indexed keywords

11 FLUORO 9,15 DIHYDROXY 15 (2 INDANYL) 16,17,18,19,20 PENTANORPROSTA 5,13 DIENOIC ACID; 11BETA FLUORO 15 EPI 15 INDANYLPROSTAGLANDIN F2 ALPHA; 17 PHENYLTRINORPROSTAGLANDIN F2 ALPHA; BIMATOPROST; CALCIUM ION; EYE DROPS; PRODRUG; PROSTAGLANDIN F2 ALPHA DERIVATIVE; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR FP; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; AMIDE; CALCIUM; CLOPROSTENOL; DRUG DERIVATIVE; HYBRID PROTEIN; LIPID; TRAVOPROST;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CELL CLONE; CELL LINE; CILIARY BODY; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; FLUOROMETRY; GLAUCOMA; HUMAN; HUMAN CELL; IMAGING SYSTEM; PRIORITY JOURNAL; BLOOD; DOSE RESPONSE; DRUG POTENTIATION; EYE; GENETICS; LIPID METABOLISM; METABOLISM; MOLECULAR CLONING; SIGNAL TRANSDUCTION;

AMIDES; CALCIUM; CILIARY BODY; CLONING, MOLECULAR; CLOPROSTENOL; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE; FLUOROMETRY; HUMANS; LIPID METABOLISM; LIPIDS; RECEPTORS, PROSTAGLANDIN; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 0037275782     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(02)00232-6     Document Type: Article

References (13)

1. H.A. Quigley. Open-angle glaucoma, N. Eng. J. Med. 328 (1993) 1097-1106.
2. M.R. Hellberg, V. Sallee, M. McLaughlin, N.A. Sharif, L. DeSantis, T.R. Dean, P.W. Zinke, Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, J. Ocular Pharmacol. Ther. 17 (2001) 421-432.
3. 2α analogue, Adv. Prostaglandin. Thrombox. Leukotr. Res. 23 (1995) 513-518.
4. T. Taniguchi, M.S.R. Haque, K. Sugiyama, N. Hori, Y. Kitazawa, Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbit, J. Ocular Pharmacol. 12 (1996) 489-498.
5. D.F. Woodward, A.H-P. Krauss, J. Chen, R.K. Lai, C.S. Spada, R.M. Burke, S.W. Andrews, L. Shi, Y. Liang, K.M. Kedzie, R. Chen, D.W. Gil, A. Kharlamb, A. Archeampong, J. Ling, C. Madu, J. Ni, P. Rix, J. Usanky, H. Usansky, A. Weber, B. Brar, L.A. Wheeler, L.J. Kaplan, The pharmacology of bimatoprost (Lumigan™), Surv. Ophthalmol. (Suppl) 45 (2001) S337-S345.
6. 3H]-9-β-(+) fluprostenol): carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor, J. Pharmac. Pharmacol. 51 (1999) 685-694.
7. 2α) receptor, J. Biol. Chem. 272 (1997) 27147-27154.
8. J.C. Jerman, S.J. Brough, R. Prinjha, M.H. Harries, J.B. Davis, D. Smart, Characterization using FLIPR of rat vanilloid receptor (rVR1) pharmacology, Br. J. Pharmacol. 130 (2002) 916-922.
9. 2α (FP) receptor, J. Pharmacol. Exp. Ther. 290 (1999) 1278-1284.
10. B.W. Griffin, P.E. Magnino, I-H. Pang, N.A. Sharif, Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization, J. Pharmacol. Exp. Ther. 286 (1998) 411-418.
11. 3, and FP prostaglandin receptor binding sites in bovine corpus luteum: characterization and correlation with functional data, J. Pharmacol. Exp. Ther. 286 (1998) 1094-1102.
12. N.A. Sharif, J.Y. Crider, S.X. Xu, G.W. Williams, Affinities, selectivities, potencies and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids, J. Pharmacol. Exp. Ther. 293 (2000) 321-328.
13. N.A. Sharif, J.Y. Crider, T.L. Davis, AL-3138 antagonizes FP prostanoid receptor-mediated inositol phosphates generation: comparison with some purported FP antagonists, J. Pharmac. Pharmacol. 52 (2000) 1529-1539.